Comparative efficacy and safety of anifrolumab for belimumab-experienced and biologic-naïve patients with systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry
- PMID: 40090613
- DOI: 10.1016/j.jbspin.2025.105882
Comparative efficacy and safety of anifrolumab for belimumab-experienced and biologic-naïve patients with systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry
Conflict of interest statement
Disclosure of interest M.A. received lecture fees from AstraZeneca and GlaxoSmithKline, and H.N. received lecture fees from AstraZeneca, GlaxoSmithKline, and Asahi Kasei Pharma. All other authors declare that they have no competing interests.
Publication types
LinkOut - more resources
Full Text Sources
